Acute Myeloid Leukemia


Upon viewing this session, you will be able to:

• discuss the appropriate use and management of small molecules recently approved for newly diagnosed or relapsed AML, highlighting:
• Maintenance with FLT3 inhibitors after allo transplant
• Recognize differentiation syndrome after IDH-targeted therapy
• Recognize mutation and gene expression profiles which may be used for prognostication and targeted therapy
• describe immunotherapies on the horizon for patients with AML and explore optimal ways to discuss goals of care


  • Gary Schiller


Member Type Price
List Price $30.00
Active, International, Emeritus, and Honorary Members $20.00
Associate, International Associate, Student, and Resident Members $20.00
back to top